|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 43.92 USD | +2.86% |
|
+0.05% | +0.21% |
| 12/02 | Biogen Inc. Announces Board Changes | CI |
| 11/02 | RBC Raises Price Target on Exelixis to $46 From $45, Keeps Sector Perform Rating | MT |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||||
Biotechnology | 143.5Cr | 161.11Cr | 183.02Cr | 216.87Cr | 232.01Cr | |||||
Total Assets | 261.62Cr | 307.15Cr | 294.24Cr | 294.77Cr | 284.44Cr | |||||
Interest Expense | - | - | - | - | - | |||||
Income Tax Expense | 6.31Cr | 5.21Cr | 4.98Cr | 16Cr | 16Cr | |||||
CAPEX | -6.42Cr | -2.77Cr | -4.05Cr | -2.84Cr | -84.29L | |||||
EBT | 29Cr | 23Cr | 26Cr | 68Cr | 94Cr | |||||
D&A | 1.36Cr | 2.09Cr | 2.57Cr | 2.88Cr | 2.91Cr | |||||
Operating Income | 29Cr | 20Cr | 17Cr | 60Cr | 87Cr | |||||
Net Income | 23Cr | 18Cr | 21Cr | 52Cr | 78Cr |
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
United States (U.S.) | 108.94Cr | 141.37Cr | 164.57Cr | 182.3Cr | 214.04Cr | |||||
Total Assets | 261.62Cr | 307.15Cr | 294.24Cr | 294.77Cr | 284.44Cr | |||||
Europe | 30Cr | 17Cr | 14Cr | 32Cr | 15Cr | |||||
Japan | 4.35Cr | 2.87Cr | 3.95Cr | 2.71Cr | 2.56Cr | |||||
Rest of The World | - | - | - | - | - |
- Stock Market
- Equities
- EXEL Stock
- Financials Exelixis, Inc.
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition